Transdermal Patch Disposal via Oxidative Decomposition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Transdermal therapeutic systems (TTS) used for chronic pain management pose a risk of abuse due to residual medicinal substances, and existing disposal methods either fail to prevent misuse or cause environmental issues, with previous solutions being either ineffective or economically and technically complex.
Innovation Solution
A multilayer structure TTS with a separate protective layer containing a chemical agent like potassium permanganate, which is stored separately and brought into contact with the used TTS to chemically decompose the active ingredient after removal from the skin, using a fibrous layer and moisture to facilitate contact and destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transdermal therapeutic systems contain larger quantity of active ingredient to maintain concentration gradient, then therapeutic effectiveness is improved, but potential for misuse and abuse increases
Solution Approach 1:
The patent applies preliminary anti-action by incorporating an inert agent into the TTS that will later render the active ingredient unusable. This preventive measure is built into the system before use, ensuring that even if the TTS is misused, the active ingredient cannot be extracted or abused because it has already been chemically deactivated by the inert agent.
Solution Approach 2:
The patent converts the harmful potential of residual active ingredient into a benefit by using the inert agent to chemically deactivate it. The same chemical interaction that would normally preserve the active ingredient's stability is repurposed to destroy its pharmacological activity, turning a security risk into a safety feature.
2Ease of operation
If patients cut up and flush used patches to dispose of them, then ease of disposal is improved, but environmental pollution and drainpipe clogging increase
Solution Approach 1:
The patent converts the harmful environmental disposal method into a beneficial process by using the inert agent to chemically deactivate the active ingredient in the TTS. This ensures that when patients flush the patches, they are disposing of chemically inactive material rather than potent medicinal substances, eliminating environmental pollution while maintaining ease of disposal.
3Reliability
If transdermal therapeutic systems contain antagonist to prevent misuse, then safety is improved, but manufacturing complexity increases
Solution Approach 1:
The patent merges the inert agent with the active ingredient in the same matrix or layer of the TTS, eliminating the need for separate compartments or complex release mechanisms. This unified structure simplifies manufacturing while maintaining the safety function, as the inert agent is already positioned to interact with the active ingredient upon application.
4Reliability
If inert agent with high reactivity is used to render active ingredient unusable, then effectiveness of disposal is improved, but shelf life and transport safety deteriorate
Solution Approach 1:
The patent applies preliminary action by pre-positioning the inert agent within the TTS structure during manufacturing, but designing it to remain dormant during storage and transport. The inert agent is formulated to only become reactive after the TTS is applied to the skin, at which point the skin's moisture or biochemical environment triggers the deactivation process, ensuring both shelf stability and effective disposal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effectively prevents improper removal and reuse of medicinal substances, ensuring reliable disposal while being easy to produce, store, and handle, with complete destruction of active ingredients within 3-4 hours, thus addressing the abuse and environmental concerns.
Implementation Method 1
the dosage form is destroyed or decomposed in a chemical reaction... contains a separate, inert agent in a solution that renders the active ingredient unusable... chemically decomposed
Implementation Method 2
a therapeutic active ingredient, preferably one from the group of analgesics, which is carried from the system to the skin by diffusion and then applied transdermally
Implementation Method 3
using a fibrous layer and moisture to facilitate contact and destruction
Data Source
AI summary
The invention relates to a means for the destructive disposal of medical active ingredients contained in transdermal therapeutic systems (= TTS). The means has a multi-layer design and contains at least one layer having agents embedded therein and at least one fiber layer. It may additionally comprise a protective layer. The means according to the invention is stored separately from the TTS. The separately stored means is brought into contact with the TTS after use of said TTS.